In patients whose clinical profiles fit AD (e.g., those with family history of the disease and/or have confirmed genetic predisposition for AD) but have their plasma p-tau in normal ranges, periodic follow-up clinical and blood biomarker assessments (e.g., annually) would be ideal to monitor for longitudinal changes in p-tau and cognitive capacity. Here, MAPT is linked to Alzheimer disease.